( December 28, 2020, 22:29 GMT | Official Statement) -- MLex Summary: The Pharmaceutical Research and Manufacturers of America filed a brief urging the US Court of Appeals for the Seventh Circuit to rule that the existence of two different entry dates in two jurisdictions in a patent settlement is not sufficient, without more, to plead an anticompetitive reverse payment. It also said that “patent thickets” are too amorphous a concept on which to base any antitrust claims. “If either proposition were to become law, life sciences companies would face substantial uncertainty surrounding the patent protections upon which the industry depends that would, in turn, jeopardize the incentives to invest in therapeutic advances so important to public health,” it argued. The appeal concerns antitrust claims filed against AbbVie, Amgen, Samsung Bioepis, and Sandoz over generic Humira.See document below. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.